Louisiana State Employees Retirement System Grows Stock Position in Glaukos Corporation $GKOS

Louisiana State Employees Retirement System lifted its stake in Glaukos Corporation (NYSE:GKOS) by 2.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,700 shares of the medical instruments supplier’s stock after buying an additional 700 shares during the period. Louisiana State Employees Retirement System’s holdings in Glaukos were worth $2,758,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of GKOS. SG Americas Securities LLC increased its holdings in shares of Glaukos by 35.2% in the first quarter. SG Americas Securities LLC now owns 4,924 shares of the medical instruments supplier’s stock worth $485,000 after buying an additional 1,283 shares during the period. Handelsbanken Fonder AB increased its holdings in shares of Glaukos by 25.2% in the first quarter. Handelsbanken Fonder AB now owns 18,400 shares of the medical instruments supplier’s stock worth $1,811,000 after buying an additional 3,700 shares during the period. Elevation Point Wealth Partners LLC increased its holdings in Glaukos by 78.2% during the 1st quarter. Elevation Point Wealth Partners LLC now owns 3,221 shares of the medical instruments supplier’s stock valued at $317,000 after purchasing an additional 1,413 shares during the period. Exchange Traded Concepts LLC increased its holdings in Glaukos by 27.5% during the 1st quarter. Exchange Traded Concepts LLC now owns 6,626 shares of the medical instruments supplier’s stock valued at $652,000 after purchasing an additional 1,430 shares during the period. Finally, Avior Wealth Management LLC increased its holdings in Glaukos by 30.1% during the 1st quarter. Avior Wealth Management LLC now owns 3,384 shares of the medical instruments supplier’s stock valued at $333,000 after purchasing an additional 782 shares during the period. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Performance

Glaukos stock opened at $86.92 on Friday. The stock’s 50 day simple moving average is $88.03 and its two-hundred day simple moving average is $92.93. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The stock has a market cap of $4.98 billion, a price-to-earnings ratio of -52.68 and a beta of 0.76. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The business had revenue of $124.12 million for the quarter, compared to analysts’ expectations of $115.49 million. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The business’s revenue was up 29.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. As a group, analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GKOS has been the topic of a number of research analyst reports. BTIG Research restated a “buy” rating and set a $118.00 price target on shares of Glaukos in a report on Wednesday, September 10th. Truist Financial reduced their price target on Glaukos from $126.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a report on Wednesday. Citigroup reduced their price target on Glaukos from $140.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, William Blair upgraded Glaukos to a “strong-buy” rating in a report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.00.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.